BERLIN, Germany, March 31, 2025 / Biotech Newswire / --

德国柏林，2025年3月31日 /生物技术新闻社/ --

ProBioGen

ProBioGen

announces the appointment of Dr. Alfred Merz, PhD, as Chief Executive Officer (CEO), effective April 1, 2025. Dr. Merz, who previously served as Chief Operating Officer (COO) and interim CEO, now assumes full leadership of the company.

宣布任命阿尔弗雷德·默茨博士为首席执行官（CEO），自2025年4月1日起生效。默茨博士此前曾担任首席运营官（COO）和临时CEO，现在将全面领导公司。

Dr. Alfred Merz joined ProBioGen in 2024 from Bayer Pharmaceuticals, where he held the position of Senior Vice President and Head of Product Supply Medical Devices. With over 30 years of international experience in manufacturing, operational excellence, and strategy development, Dr. Merz has worked for leading pharmaceutical and biotech companies, including Bayer and Novartis.

阿尔弗雷德·默茨博士于2024年从拜耳制药加入ProBioGen，此前他担任拜耳制药高级副总裁兼医疗器械产品供应主管。默茨博士在制造、卓越运营和战略发展方面拥有超过30年的国际经验，曾任职于包括拜耳和诺华在内的领先制药和生物技术公司。

His expertise will be instrumental in driving the company's next growth phase, while solidifying ProBioGen's position as a trusted partner in biopharmaceutical development and manufacturing for clinical and commercial supply, recognized for its scientific acumen, client-oriented flexibility, and reliability..

他的专业知识将对推动公司的下一增长阶段起到关键作用，同时巩固ProBioGen作为生物制药开发和临床及商业化生产中值得信赖的合作伙伴地位，以其科学敏锐性、以客户为导向的灵活性和可靠性而广受认可。

'ProBioGen has a strong legacy of innovation and excellence in CDMO services and technologies,'

“ProBioGen在CDMO服务和技术方面有着强大的创新和卓越的传统，”

said Dr. Alfred Merz.

阿尔弗雷德·默茨博士说。

'I am honored to lead this outstanding team as we accelerate our growth, expand our capabilities, and continue delivering high-quality solutions for our pharma and biotech partners.'

“在我加快我们的成长、拓展我们的能力并继续为我们的制药和生物技术合作伙伴提供高质量解决方案的过程中，我感到很荣幸能够领导这支卓越的团队。”

'Alfred embodies impressive leadership and business acumen,'

“阿尔弗雷德展现了令人印象深刻的领导才能和商业智慧，”

stated Dr. Wafik Bardissi, Chairman of ProBioGen's Supervisory Board and CEO of Minapharm Pharmaceuticals SAE.

普罗拜奥根监事会主席兼米纳制药公司首席执行官瓦菲克·巴迪西博士说道。

'His strategic expertise is vital to accelerating ProBioGen's growth, advancing therapeutic innovation globally through proprietary technologies, and fostering impactful partnerships while enhancing operational excellence.'

“他的战略专业知识对于加速ProBioGen的增长、通过专有技术推动全球治疗创新、促进有影响力的合作伙伴关系以及提升运营卓越性至关重要。”

With Dr. Merz at the helm, ProBioGen is well-positioned to continue its legacy and enter the next phase of growth. As a leading CDMO provider for biologics and advanced therapies, ProBioGen offers comprehensive services paired with cutting-edge technologies, ensuring on-time delivery, top quality, and tailored solutions.

在梅尔茨博士的带领下，ProBioGen 已为延续其传奇并进入下一个增长阶段做好了充分准备。作为生物制品和先进疗法的领先 CDMO 供应商，ProBioGen 提供全面的服务，并结合尖端技术，确保准时交付、顶级质量和定制化解决方案。

The customer-centric company remains committed to driving innovation and meeting the growing demand for life-saving biopharmaceuticals, setting the standard for accelerated development in the industry..

以客户为中心的公司仍然致力于推动创新，满足对拯救生命的关键生物制药日益增长的需求，为行业加速发展树立标杆。

Caption:

标题：

Dr. Alfred Merz

阿尔弗雷德·默茨博士

For high resolution please click the image.

请单击图像以获得高分辨率。

About

关于

ProBioGen

普罗生物ген

ProBioGen is a Berlin-based biotech company, a so-called Contract Development and Manufacturing Organization (CDMO) and technology provider that operates globally.

ProBioGen是一家总部位于柏林的生物技术公司，是一家所谓的合同开发和制造组织（CDMO）和技术提供商，在全球范围内运营。

It specializes in developing and manufacturing biopharmaceutical active ingredients, viral vectors and vaccines, while also developing and outlicensing proprietary technologies that enhance product quality and features. Founded in 1994 as a spin-off of Charité, a widely recognized hospital known as one .

该公司专注于开发生物制药活性成分、病毒载体和疫苗，同时开发并授权能够提升产品质量和特性的专有技术。公司成立于1994年，是从广为人知的沙里泰医院分拆出来的一家公司。

of the best

最好的

in the world. 30 years later, almost 300 employees work at ProBioGen's three locations in Berlin.

在世界上。30年后，近300名员工在柏林的ProBioGen三个地点工作。

Every day, they contribute to the creation of new therapies in medicine and groundbreaking innovations worldwide through their creative and meticulous work. ProBioGen's growth strategy is driven by the expansion of the service value chain through organic growth and potential acquisitions. Diversification is a complementary driver, while the focus is strict on enabling the development of biopharmaceuticals for tomorrow..

每一天，他们都通过其富有创意且细致入微的工作，为医学领域新疗法的创造以及全球范围内的突破性创新作出贡献。ProBioGen 的增长战略是通过自然增长和潜在收购来推动服务价值链的扩展。多元化是一个补充性的驱动因素，而重点则严格放在助力开发生物制药以满足未来需求上。

For more information about ProBioGen, follow us on

欲了解有关ProBioGen的更多信息，请关注我们

LinkedIn

领英

.

。

Contacts

联系人

ProBioGen

普罗拜根

Dr. Gabriele Schneider

加布里埃尔·施耐德博士

Chief Business Officer

首席商务官

This email address is being protected from spambots. You need JavaScript enabled to view it.

该电子邮件地址正受到防垃圾邮件机器人的保护。您需要启用 JavaScript 才能查看它。

ProBioGen Press Contact

ProBioGen 媒体联系人

Sarah Wandrey

萨拉·万德雷

Senior Communications Manager

高级传播经理

This email address is being protected from spambots. You need JavaScript enabled to view it.

该电子邮件地址正受到垃圾邮件程序的保护。您需要启用 JavaScript 才能查看它。

Keywords: Leadership; Appointments and Schedules; Drug Development;  Cell Line; Technology; Cell Culture Techniques; Culture Media; Cell Proliferation; Cell Line Development; Cells, Cultured; Biological Products; Productivity; Dr. Alfred Merz; Chief Executive Officer (CEO); ProBioGen; Berlin, Germany; Manufacturing; Biopharmaceutical Development; Biopharmaceutical Manufacturing; Clinical Supply; Commercial Supply; CDMO Services; Biologics; Tailored Solutions; Accelerated Development; Contract Development and Manufacturing Organization (CDMO); Technology Provider.

关键词：领导力；任命与日程；药物开发；细胞系；技术；细胞培养技术；培养基；细胞增殖；细胞系开发；培养细胞；生物制品；生产力；阿尔弗雷德·默茨博士；首席执行官（CEO）；ProBioGen；德国柏林；制造；生物制药开发；生物制药生产；临床供应；商业供应；CDMO服务；生物制品；定制解决方案；加速开发；合同开发和制造组织（CDMO）；技术提供商。

Source: Biotech Newswire

来源：生物技术新闻专线